论文部分内容阅读
在过去20年里,多发性骨髓瘤(MM)的疗效无根本改变,迄今仍令人失望。对于初治的MM,以烷化剂和强的松为基础的联合化疗有效率为40%～60%,中数生存期为20～36月,但所有患者最终都要复发。VAD方案(长春新碱、阿霉素和地塞米松)使难治性MM患者的疗效有所改善,但有效期很短。大剂量马法兰(80～140mg/m~2)加(或不加)
In the past two decades there has been no fundamental change in the efficacy of multiple myeloma (MM), which has so far been disappointing. For untreated MM, combination chemotherapy based on alkylating agents and prednisone has efficiencies of 40% -60% and median survival of 20-36 months, but all patients eventually relapse. The VAD regimen (vincristine, doxorubicin, and dexamethasone) has improved the efficacy of refractory MM but has a short duration of efficacy. High-dose melphalan (80 ~ 140mg / m ~ 2) plus (or not)